How can Integral Molecular help me accelerate my vaccine development program?
Virology Experience
SARS-CoV-2 (Novel Coronavirus) Research initiatives
We have mobilized two platform technologies to support the discovery of vaccines and therapeutics to combat COVID-19. Shotgun Mutagenesis is being used to epitope map coronavirus MAbs to reveal their mechanism of action and define how vaccines and the natural human immune system can effectively neutralize the virus. The Membrane Proteome Array will aid target discovery by identifying new coronavirus receptors used by SARS-CoV-2 to invade cells.
Learn more about our COVID-19 response efforts or to view our webinar, "SARS-CoV-2 Reporter Virus for Neutralization Assays"
Dengue and Zika Reporter Viruses
Our Flavivirus Reporter Virus Particles (RVPs) are replication-incompetent viruses that enable safe, easy, and reproducible viral infectivity, neutralization, and enhancement using standard detection instrumentation. RVPs incorporate virus-specific prM/E proteins. Antigenically identical to wild-type viruses, RVPs contain a modified RNA genome and express convenient optical reporter genes upon cellular infection. RVPs are available as quality-controlled, ready-to-use reagents that provide an efficient alternative to plaque assays. Dozens of commercial and academic laboratories use our RVP system.
See RVP application notes
Epitope Mapping on Viral Targets
At Integral Molecular, we use Shotgun Mutagenesis to map epitopes of monoclonal antibodies (MAbs) against viral envelope proteins. This system allows us to map neutralizing or non-neutralizing MAbs, even for conformational epitopes, at single-amino-acid resolution. With a success rate of >95%, we have mapped epitopes for 500+ MAbs to date for therapeutic, vaccine, and research studies. Applications include determining neutralizing structures, mapping immune responses, optimizing MAb cocktails, and intellectual property protection.
Pre-validated libraries for select viral envelopes are available for expedited project turnaround
Protein Engineering for Vaccine Development
We offer protein engineering solutions for your vaccine discovery needs. Using functional screening of mutation libraries, we can identify individual amino acids or regions important for key viral envelope functions, such as infectivity, budding, and protein folding. We apply comprehensive and combinatorial mutagenesis strategies (point mutations and/or chimeras) to identify vaccine variants with desired characteristics or improved manufacturing properties.
Learn about our experience with protein engineering
Antibodies against Viral Targets
We offer critical reagent antibodies targeting select viruses. In addition, our MPS antibody discovery platform enables the isolation and optimization of antibodies against the most challenging viral targets. The platform harnesses the strength of Integral Molecular's 15+ years of membrane protein expertise and proprietary technologies, including Lipoparticle antigen presentation, DNA+Lipoparticle immunization, and microfluidic B-cell cloning.
Learn about our MPS Antibody Discovery Platform
Viral Receptor Identification using the Membrane Proteome Array™
The Membrane Proteome Array™ is a high-throughput, cell-based platform with applications for identifying cell-surface receptors for viruses, and specificity profiling for antibodies and other biologics. The Membrane Proteome Array™ represents the largest membrane protein library yet assembled, consisting of over 6,000 unique, individually expressed membrane proteins used to detect binding events directly on the surface of human cells. Using the Membrane Proteome Array™, we have identified putative receptors for Zika and Ebola viruses.
Learn more about the Membrane Proteome Array"We sought out Integral Molecular for their expertise in the Dengue field. The team has been great to work with, and we have greatly benefited from their new technologies."
Validated Virology Tools
| Virus | RVPs | Pre-validated Libraries For Epitope Mapping |
|---|---|---|
| SARS-CoV-2 |  | Spike protein |
| SARS-Cov-2-D614G | | |
| SARS-CoV-1 | | |
| MERS-CoV | | |
| Dengue Virus 1 | | prM/E |
| Dengue Virus 2 | | prM/E |
| Dengue Virus 3 | | prM/E |
| Dengue Virus 4 | | prM/E |
| Zika Virus | | prM/E |
| Ebola Virus | GP | |
| Chikungunya Virus | E2/E1 | |
| HIV | gp160 | |
| Hepatitis C Virus | E1/E2 | |
| Hepatitis B Virus | sAg | |
| Respiratory Syncytial Virus | F protein |
Vaccine Development Publications
"I have worked with Integral Molecular on various virology projects, including mapping binding sites of antibodies and maturation of an antibody targeting a viral protein. Integral has expertise/insights into structure based antibody design which helped a lot."
Frequently Asked Questions
